A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies

Cites Work

Title not available (Why is that?)
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
Dose-Finding Based on Efficacy-Toxicity Trade-Offs
A weakly informative default prior distribution for logistic and other regression models
Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
Adaptive Rejection Metropolis Sampling within Gibbs Sampling
A utility‐based design for randomized comparative trials with ordinal outcomes and prognostic subgroups
A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
Bayesian optimal interval designs for phase I clinical trials

Related Items (7)

TITE-gBOIN-ET: time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes ⋮ DROID: dose-ranging approach to optimizing dose in oncology drug development ⋮ REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors ⋮ uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials ⋮ A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials ⋮ TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy ⋮ Commentary on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies

This page was built for publication: A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6627253)